• Menu
  • Skip to right header navigation
  • Skip to main content
  • Skip to footer

Before Header

  • GLOBAL LOCATIONS

Axis Clinicals

Contract Research Organization

  • Participants
    • Upcoming Studies
    • FAQs
  • About Us
    • Clinical
    • Bioanalytical
    • Our Team
  • Services
    • Complex Pharmacology and 505(b)(2)
    • Bioavailability/
      Bioequivalence
    • Topical Delivery – Dermatology
    • Clinical Trial Management
  • Careers
  • News
  • Sponsor Contact
  • Participants
    • Upcoming Studies
    • FAQs
  • About Us
    • Clinical
    • Bioanalytical
    • Our Team
  • Services
    • Complex Pharmacology and 505(b)(2)
    • Bioavailability/
      Bioequivalence
    • Topical Delivery – Dermatology
    • Clinical Trial Management
  • Careers
  • News
  • Sponsor Contact

AXIS Clinicals Announces ERT Certification.

December 16, 2019

Dilworth, MN – Axis Clinicals USA announces they have received ERT Certification. The Certification program ensures sites are proficient in collecting the highest quality ECG data. This is done by conducting Phase I QT assessments using ERT’s proprietary Expert Precision QT approach.

With Axis Clinicals being ERT certified, we are able to work with biopharmaceutical clients making recommendations on the design, conduct, analysis, and interpretation of continuous Holter recordings to assess the cardiac safety profile of a drug during various pharmacology studies. AXIS’ encompassing clinical and bioanalytical operations at our purposed built facility in Dilworth, Minnesota allows expedited results with bioanalysis samples walked to an adjacent laboratory to the clinic, ideal for First-In-Human, Single Ascending Dose/Multiple Ascending Dose and Cardiac Safety pharmacology studies conducted at any time of a drug developments’ program.

About AXIS Clinicals USA
Our Dilworth, Minnesota (Fargo, ND area) Clinical/bioanalytical operations is centrally located in the US with a proven history of enrolling large panels of compliant healthy volunteers and targeted patient populations for complex studies.

For more information
John Pottier – Vice President, Business Development
j.pottier@axisclinicals.com

Previous Post: « Axis Clinicals hires Dr. Michael Willett
Next Post: AXIS Continues Clinical Research During COVID-19 Restrictions »

Footer

Participants

  • Upcoming Studies
  • FAQs

About

  • Clinical
  • Bioanalytical
  • Our Team

Services

  • Complex Pharmacology and 505(b)(2)
  • Bioavailability/Bioequivalence
  • Topical Products (Dermatology)
  • Clinical Trial Management

Info

  • Careers
  • Sponsor Contact
  •  218-284-AXIS

Copyright © 2021 · Axis Clinicals